Inflammatory responses in SARS-CoV-2 associated Multisystem Inflammatory Syndrome and Kawasaki Disease in children: An observational study

PLoS One. 2022 Nov 30;17(11):e0266336. doi: 10.1371/journal.pone.0266336. eCollection 2022.

Abstract

Multisystem Inflammatory Syndrome in Children (MIS-C) is a severe inflammatory disease in children related to SARS-CoV-2 with multisystem involvement including marked cardiac dysfunction and clinical symptoms that can resemble Kawasaki Disease (KD). We hypothesized that MIS-C and KD might have commonalities as well as unique inflammatory responses and studied these responses in both diseases. In total, fourteen children with MIS-C (n=8) and KD (n=6) were included in the period of March-June 2020. Clinical and routine blood parameters, cardiac follow-up, SARS-CoV-2-specific antibodies and CD4+ T-cell responses, and cytokine-profiles were determined in both groups. In contrast to KD patients, all MIS-C patients had positive Spike protein-specific CD3+CD4+ T-cell responses. MIS-C and KD patients displayed marked hyper-inflammation with high expression of serum cytokines, including the drug-targetable interleukin (IL)-6 and IFN-γ associated chemokines CXCL9, 10 and 11, which decreased at follow-up. No statistical differences were observed between groups. Clinical outcomes were all favourable without cardiac sequelae at 6 months follow-up. In conclusion, MIS-C and KD-patients both displayed cytokine-associated hyper-inflammation with several high levels of drug-targetable cytokines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • COVID-19* / complications
  • Child
  • Connective Tissue Diseases*
  • Cytokines
  • Humans
  • Inflammation
  • Interleukin-6
  • Mucocutaneous Lymph Node Syndrome* / complications
  • SARS-CoV-2

Substances

  • Antibodies, Viral
  • Cytokines
  • Interleukin-6

Supplementary concepts

  • pediatric multisystem inflammatory disease, COVID-19 related

Grants and funding

The “Clinical features of COVID-19 in Pediatric Patients” (COPP)-study is funded by the #wakeuptocorona crowdfund initiative of the Bontius Stichting and the Leiden University Fund. Receiver of the grant EB The Kawasaki study is funded by the Dutch Foundation Kind & Handicap (The Hague, The Netherlands) and an anonymous donor through the AMC foundation. Reciever of the grant is TK. The sponsors had no role in the study design, the data collection and analysis, the writing of the report, or the decision to submit the manuscript for publication.